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Abstract
Background: The discovery of the inherited disorders of creatine (Cr) synthesis and transport in the last few years
disclosed the importance of blood Cr supply for the normal functioning of the brain. These putatively rare diseases
share a common pathogenetic mechanism (the depletion of brain Cr) and similar phenotypes characterized by
mental retardation, language disturbances, seizures and movement disorders. In the effort to improve our
knowledge on the mechanisms regulating Cr pool inside the nervous tissue, Cr transport and synthesis and related
gene transcripts were explored in primary cultures of rat cerebellar granule cells and astrocytes.
Methods: Cr uptake and synthesis were explored in vitro by incubating monotypic primary cultures of rat type I
astrocytes and cerebellar granule cells with: a) D3-Creatine (D3Cr) and D3Cr plus b-guanidinopropionate (GPA, an
inhibitor of Cr transporter), and b) labelled precursors of Guanidinoacetate (GAA) and Cr (Arginine, Arg; Glycine,
Gly). Intracellular D3Cr and labelled GAA and Cr were assessed by ESI-MS/MS. Creatine transporter (CT1), L-arginine:
glycine amidinotransferase (AGAT), and S-adenosylmethionine:guanidinoacetate N-methyltransferase (GAMT) gene
expression was assessed in the same cells by real time PCR.
Results: D3Cr signal was extremely high in cells incubated with this isotope (labelled/unlabelled Cr ratio reached
about 10 and 122, respectively in cerebellar granule cells and astrocytes) and was reduced by GPA. Labelled Arg
and Gly were taken up by the cells and incorporated in GAA, whose concentration paralleled that of these
precursors both in the extracellular medium and inside the cells (astrocytes). In contrast, the increase of labelled Cr
was relatively much more limited since labelled Cr after precursors’ supplementation did not exceed 2,7%
(cerebellar granule cells) and 21% (astrocytes) of unlabelled Cr. Finally, AGAT, GAMT and SLC6A8 were expressed in
both kind of cells.
Conclusions: Our results confirm that both neurons and astrocytes have the capability to synthesize and uptake
Cr, and suggest that at least in vitro intracellular Cr can increase to a much greater extent through uptake than
through de novo synthesis. Our results are compatible with the clinical observations that when the Cr transporter is
defective, intracellular Cr is absent despite the brain should be able to synthesize it. Further research is needed to
fully understand to what extent our results reflect the in vivo situation.
* Correspondence: vincenzo.leuzzi@uniroma1.it
† Contributed equally
5Dept of Child Neurology and Psychiatry, La Sapienza Università di Roma, Via
dei Sabelli 108, Rome 00185, Italy
Full list of author information is available at the end of the article
Carducci et al. BMC Neuroscience 2012, 13:41
http://www.biomedcentral.com/1471-2202/13/41
© 2012 Carducci et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Keywords: L-arginine:glycine amidinotransferase (AGAT), Creatine transporter (CT1), S-adenosylmethionine: guanidi-
noacetate N-methyltransferase (GAMT), Energetic metabolism in CNS, Mass spectrometry, Creatine transporter gene
(SLC6A8)
Background
The discovery of the inherited disorders of Cr metabo-
lism has significantly improved the knowledge on the
role of creatine (Cr) in the human brain energetic meta-
bolism [1,2] through the observation of the clinical con-
sequence of Cr deficiency. These putatively rare diseases
are due either to defects of the enzymes devoted to Cr
synthesis (L-arginine:glycine amidinotransferase (AGAT,
EC 2.1.4.1) [3] and S-adenosylmethionine:guanidinoace-
tate N-methyltransferase (GAMT, EC 2.1.1.2) [4]) - or to
defects of the Cr transporter (CT1) [5,6]. They all share a
common pathogenetic mechanism (the depletion of brain
Cr) and similar phenotypes characterized by mental
retardation, language disturbances, seizures and move-
ment disorders. The clinical symptoms in AGAT and
GAMT deficiencies are partially reversed by oral Cr sup-
plementation [7,8], and possibly prevented by an early
onset treatment [9,10], which also restores almost totally
the brain Cr signal [11]. On the contrary, no effective
treatment is available for the defect of CT1: while the
supplementation of the precursors of Cr, Arginine (Arg)
and Glycine (Gly), restores the Cr synthesis in peripheral
cells in vitro [12], it results in only a mild clinical
improvement with scarce [13] or absent [14] increase of
brain Cr signal in vivo. So these rare metabolic disorders
disclosed the importance of blood Cr supply for the nor-
mal functioning of the brain, even though AGAT and
GAMT are widely expressed in the nervous tissue [15]
where Cr synthesis certainly occurs [16,17].
It has been hypothesized that in the absence of CT1,
neurons can not take up glial-synthesized Cr or guanidi-
noacetate (GAA), so suggesting a glia-neuron interplay in
brain Cr homeostasis [18]. According to this model, we
would expect a different distribution of the components
involved in Cr metabolism (transport and synthesis) in
neurons and glial cells. In the effort to improve our
knowledge on the mechanisms regulating Cr pool inside
the nervous tissue, Cr synthesis was explored in primary
cultures of rat cerebellar granule cells and astrocytes by
using Arg and Gly labelled by stable isotopes. Since these
compounds are substrates of AGAT (Arg and Gly) and
GAMT (GAA), the detection of the labelled products
makes it possible to speculate on the distribution of these
enzymes in different cells. Moreover, the role of CT1 was
tested by incubating cerebellar granule cells and astro-
cytes with labelled Cr in the presence and absence of
guanidinopropionate (GPA), a specific inhibitor of CT1.
Finally CT1 (SLC6A8), GAMT and AGAT gene
expression was investigated by the identification and
quantification of their transcripts in the same kind of
nervous cells in comparison with several other tissues.
Methods
Chemicals and reagents
D3-Creatine (D3Cr) was purchased from CDN isotopes
(Quebec, Canada).
13 C2-Guanidinoacetic acid ([1,2-
13 C2]
GAA) was purchased from D r .H e r m a nJ .t e nB r i n k
(Amsterdam, Netherlands). L-[guanido-
15 N2]arginine:HCl
([
15 N2]Arg) and [
13 C2,
15N]glycine ([
13 C2,
15 N]Gly) were
obtained from Cambridge Isotopes Laboratories Inc. (Mas-
sachusetts, USA). GPA, Gly, Arg, GAA, and Cr were
obtained from Sigma-Aldrich (St Luis, MO, USA). HPLC
grade methanol and formic acid were obtained from
Merck (Darmstadt, Germany). 3 N HCl in n-butanol solu-
tion was purchased from Regis Technologies Inc (Morton
Grave, USA). All solutions were prepared using highly
purified water produced by a Milli-RO/Milli-Q system
(Millipore, Bedford, Ma, USA). Centricone filters were
obtained from Millipore (Millipore, Bedford, Ma, USA).
Wistar rats were obtained from Harlan Italy, S. Pietro al
Natisone Udine. Twenty mm poly-l-lysine-coated glass
coverslips were obtained from Warner Instruments LLC
(Hamden, CT USA). Basal Eagle’s culture medium, fetal
calf serum, gentamicin and cytosine arabinoside were
obtained from Sigma Aldrich (St Luis, MO, USA). PBS
containing trypsin, bovine serum albumin, DMEM, fetal
bovin serum, penicillin/streptomycin, L-glutamine were
obtained from Euroclone (Pero - Milano Italy).
Rat cell culture
Cerebellar granule cells were prepared from 8-day-old
Wistar rats as previously described [19]. The cells were
plated at a density of 1 × 10
6 per dish on 20 mm poly-l-
lysine-coated glass coverslips and maintained in Basal
Eagle’s culture medium, containing 10% fetal calf serum,
100 μg/ml gentamicin and 25 mmol/L KCl, at 37°C in a
humidified 95% air, 5% CO2 atmosphere. Cultures were
treated with 10 μmol/L cytosine arabinoside from day 1 in
order to minimize proliferation of non-neuronal cells.
Primary cultures of rat type I astrocytes were established
as previously reported [20]. Briefly, two-day-old Wistar
rats were sacrificed by decapitation; brain cortices were
rapidly removed and separated from meninges. Brains
were minced and incubated in PBS containing trypsin
(0.125% at 37°C. for 15 min). Digestion was stopped add-
ing PBS containing 1% bovine serum albumine and was
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persion was plated into 75 cm
2 flask and cultured in
DMEM supplemented with 10% fetal bovin serum, penicil-
lin/streptomycin (10 mmol/L), L-glutamine (2 mmol/L)
and maintained in 5% CO2 atmosphere at 37°C. At conflu-
ence, flasks were shaken in rotation plates to remove
microglia and type II astrocytes. Adherent cells were then
divided (3:1 ratio) to grow a P1 generation. From conflu-
ent, P1 flasks was obtained a P2 generation of astrocytes
that was used for most experiments. In some cases, a third
(P3) generation was obtained, and enzyme expression was
compared in the 3 (P1, P2 and P3) astrocyte generations.
All animal experiments were carried out with authoriza-
tion by the Italian ministry of Health and in compliance
with the animal care requirements that are requested by
Italian law (law D.L. 27.1.1992 n. 116, in agreement with
the European Union directive 86/609/CEE).
Cell treatment
For Cr uptake experiments, rat cerebellar granule cells and
astrocytes were incubated for 24 hours in a culture med-
ium containing1 mmol/L D3Cr and with 1 mmol/L D3Cr
plus 1 mmol/L GPA. D3Cr concentration was in accord
with previously reported Cr incubation experiments [21].
For Cr and GAA synthesis experiments, astrocytes were
incubated for 24 hours with [
15 N2]Arg and [
13 C2,
15N]Gly
at three different concentrations (5 mmol/L, 10 mmol/L,
and 15 mmol/L). By contrast neuronal cerebellar granule
cells were incubated with [
15 N2]Arg and [
13 C2,
15N]Gly at
the single concentration of 10 mmol/L. This was done in
order to optimize the number of cells available for each
experiment, given the fact that neurons proliferated much
less than astrocytes. Labelled precursor concentrations
were in accord with incubation experiments previously
reported in lymphoblasts [12]. For each experiment a sam-
ple of cells incubated in medium without labelled precur-
sors (control sample) was included.
After 24 hours of incubation the medium was aspirated,
cells were washed twice with 10 ml of saline solution and
detached from the flask’s wall with trypsin. Afterwards, the
cells were rapidly washed twice with 10 ml of saline solu-
tion by suspension and centrifugation at 1200 g for
10 min, to remove any contamination of labelled amino
acids; pellets were then suspended into 100 μl of saline
solution and stored frozen at -80°C until analysis. To lysate
the cells, the pellets were frozen and thawed for six times
at -70°C, placed in the ultrasonic bath for 30’and then cen-
trifuged at 15000 g for 30’. The supernatant was recovered,
an aliquot was used for protein assay (Bio-rad, Hercules,
CA, USA) and the remaining was deproteinized using the
Centricon filters at 5000 g for 50’. The cell extract was
then analysed by ESI-MS/MS. The incubation experiments
were replicated 3 times and the cell extracts were analysed
twice.
MS/MS analysis
ESI-MS/MS was used for the analysis of the cell extracts.
In GAA and Cr synthesis experiments Gly, [
13 C2,
15N]Gly,
Arg, [
15 N2]Arg, GAA, [1,2-
13 C2,
15 N3]GAA, Cr and [1,2-
13 C2,
15N3]Cr in the cell extract were simultaneously
determined. For the study of CT1 expression Cr, D3Cr
and GAA in the cell extracts were determined.
The cell extracts were diluted 1:5 with methanol/water
(80/20 v/v) containing the internal standard [1,2-
13 C2]
GAA in order to obtain a final concentration of
0.5 μmol/L. Then the sample was dried under a nitrogen
flow at 45°C using an EvapArray Sample Concentator
(Porvair Advanced Materials, UK) and derivatized to
butyl esters using 3 mol/L HCl in n-butanol solution at
60°C for 30 min. After derivatization the sample was
dried under a nitrogen flow at 45°C and then recovered
with 100 μl of methanol/water solution (80:20) contain-
ing 0.1% formic acid. Twenty microliters of the obtained
sample was injected for the ESI-MS/MS analysis.
An Agilent 1100 micropump (Agilent Technologies,
Wilmington, DE, USA) and a Series 200 autosampler
(Perkin Elmer, USA) were used for solvent delivery and
automated sample introduction. Mobile phase was
methanol/water (80:20) at a flow rate of 40 μl/min.
A triple quadruple mass spectrometer API 2000 (ABI
Sciex, Toronto, Canada) equipped with a TurboIonSpray
s o u r c ew a su s e d .T h ed a t aw e r ea c q u i r e da n dp r o c e s s e d
using Analyst 1.1. Resolution and calibration adjustments
of quadrupoles were made by direct infusion at a 10 μl/
min of a 0.1 mmol/L polypropyleneglycole solution by an
infusion pump. Q1 and Q3 were used at unit and high
resolution respectively. Turbo ion spray source was oper-
ated in the positive ion mode at 350°C with a drying-gas at
20 psi and a capillary voltage of 5500 V. Nitrogen was used
as curtain and collision gas. Multiple reaction monitoring
was used for the detection of [M + H]
+ and product ions.
The declustering potentials were 23, 27, 19 and 20 V, colli-
sion exit potential were 2.8, 2.0, 0.4, and 10 V and collision
energy were 19, 26, 45 and 12 eV for GAA, Cr, Arg, Gly
respectively and the same parameters were used for their
isotopomers.
As result of the GAA and Cr synthesis experimental
conditions, labelled and unlabelled precursors coexisted
inside the cells and therefore we obtained enzyme pro-
ducts with a different number of stable isotopes (monola-
belled, trilabelled and pentalabelled products). Since the
higher concentration of the labelled in respect to unla-
belled precursors, the pentalabelled forms ([1,2-
13
C2,
15N3]GAA and [1,2-
13 C2,
15N3]Cr) were prevalent.
Therefore we selected them as reference compounds,
also considering that their signals were far from isotopic
distribution of the natural compounds.
The ion transitions for the labelled products [1,2-
13
C2,
15N3]GAA and [1,2-
13 C2,
15N3]Cr were defined upon
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compounds. The fragmentation of the protonated mole-
cular ion of GAA, producing the fragment ion at 101.1
m/z, involves the loss of a molecule of butene and
ammonia, while the formation of 90.1 m/z by proto-
nated Cr, involves the loss of a molecule of butene and
cyanamide (Figure 1). According to this considerations
we used 105.0 and 93.1 m/z product ions for the quanti-
fication of respectively [1,2-
13 C2,
15N3]GAA and [1,2-
13
C2,
15N3]Cr.
The ion transitions were reported in Table 1. The
quantitative determination of Gly, [
13 C2,
15 N]Gly, Arg,
[
15 N2]Arg, Cr, [1,2-
13 C2,
15 N3]Cr and D3Cr were
obtained using internal standard calibrations. For the
construction of calibration curves four different concen-
trations of [
13 C2,
15N]Gly, [
15 N2]Arg and D3Cr were
used and the linear correlation coefficient was in all
cases higher than 0.999. The isotope dilution method
for the quantitation of labelled and unlabelled GAA was
used.
Linearity, recovery, within-run precision (data not
shown), and sensitivity (the LOD and LOQ, Table 1)
were studied demonstrating that this method was sensi-
tive, accurate and precise.
Real time PCR
RNA from different Rattus norvegicus (Sprague Dawley)
tissues was obtained. RNA was isolated from Kidney,
Liver, and astrocytes using RNeasy Mini Kit (QIAGEN,
Milan, Italy), from cerebellar granule cells, using RNeasy
Lipid Tissue Mini kit (QIAGEN, Milan, Italy) and from
blood using QIAamp RNA Blood Minikit (QIAGEN,
Milan, Italy) as described from manufacturer. cDNA
synthesis from total RNA was performed with High
Capacity cDNA Archive Kit (Applera Italia, Monza,
Italy). The resulting cDNA template, at a concentration
of 50 ng/μl, was subjected to relative-quantitative Real-
time PCR using Taqman gene expression assays (Applera
Italia, Monza, Italy), the TaqMan Universal PCR Master
Mix (Applera Italia, Monza, Italy) and the Two-Step
Real-Time PCR System (Applera Italia, Monza, Italy).
Quantitative Real Time PCR analysis of AGAT, GAMT
and SLC6A8 mRNA expression were carried out in a
Two-Step Real-Time PCR System using the TaqMan Rat
Gene Expression Assays Rn00562952_m1 for target gene
GAMT (EC 2.1.1.2), Rn00578954_m1 for target gene
AGAT (EC 2.1.4.1), Rn00506029_m1 for target gene
SLC6A8 (Solute carrier family 6 member 8) and
Rn99999916_s1 for the internal normalization gene
GAPDH (Applera Italia, Monza Italy). For quantitative
Real Time PCR analysis, each sample was run in tripli-
cates and the entire analysis was confirmed at list twice.
Each run included a no template control (NTC) to test
for contamination of assay reagents. After an initial
Amperase UNG Activation at 50°C for 2 min, and a 95°C
denaturation for 10 min, the reactions were cycled 40
times with a 95°C denaturation for 15 s, and a 60°C
annealing for 1 min. Three types of controls aimed at
detecting genomic DNA contamination in the RNA sam-
p l eo rd u r i n gt h eR e v e r s eT r a n s c r i p t i o n( R T )o r
Figure 1 Analysis by MS/MS: fragmentation by collision-induced dissociation (CID). Fragmentation pattern and selected ion transitions (m/
z) of butylated [1,2-
13 C2,
15N3]GAA and [1,2-
13 C2,
15N3]Cr used for MS/MS analyses are shown.
Table 1 Parent and product ion transitions used for
analysis by mass spectrometry
Parent ion
m/z
Product ion
m/z
LOD
(nmol/L)
LOQ
(nmol/L)
Gly 132.1 76.1 - -
[
13C2,
15N]Gly 135.1 78.6 8 30
Arg 231.2 70.2 - -
[
15N2]Arg 233.2 70.2 24 26
GAA 174.1 101.1 - -
[1,2-
13C2,
15N3]GAA, 179.1 105.0 30 50
Cr 188.1 90.1 - -
[1,2-
13C2,
15N3]Cr 193.1 93.1 5 8
D3Cr 191.2 93.1 2 3
[1,2-
13C2]GAA (IS) 176.1 103.1 - -
Parent and product ion transitions used in MRM and lower detection and
quantitation limits are reported. The LOD and LOQ were estimated analyzing
ten blank samples and were calculated adding to the mean concentration
respectively 3 and 10 SD.
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included: a RT mixture without reverse transcriptase, a
RT mixture including the enzyme but no RNA, negative
control (reaction mixture without cDNA template). Rela-
tive quantification was performed using the comparative
threshold (CT) method after determining the CT values
for reference (GAPDH) and target (AGAT, GAMT and
SLC6A8) genes in each sample sets according to the 2
-
ΔΔCT method. Changes in mRNA expression level were
calculated after normalization to GAPDH. As calibrator
sample we used cDNA from arbitrarily selected control
cell line or tissue.
Statistical analysis
Unless otherwise indicated, all data are presented as the
mean ± SD. Student’s t-test was used to determine the
significance of differences between two group means.
The relationship between two variables was tested using
linear regression analysis. For statistical evaluation
Statistica (StatSoft, Tulsa, USA) was used.
Results
Cr uptake
To investigate the functional expression of CT1 in cerebel-
lar granule cells and astrocytes these cells were incubated
with D3Cr, and its uptake was assessed in the presence or
absence of GPA. After 24 hours of incubation with
1 mmol/L D3Cr, both cerebellar granule cells and astro-
cytes showed a high intracellular accumulation of the
labelled compound (24.4 ± 5.3 and 207.5 ± 119.6 nmol/
mg protein, respectively). These values were as an average
10 and 122 times higher, respectively, than those of the
endogenous (unlabelled) Cr, that were 2.5 ± 0.9 and 1.7 ±
0.6 nmol/mg protein, respectively in rat cerebellar granule
cells and astrocytes. The addition of GPA to the culture
medium resulted in 77 ± 5% and 68 ± 1% inhibition of the
D3Cr uptake in cerebellar granule cells and astrocytes,
respectively (Figure 2) and the difference in D3Cr accumu-
lation in the presence and absence of GPA was signifi-
cantly different (paired t-test, N = 6, p = 0.006 and p =
0.039 for granule cells and astrocytes, respectively), thus
demonstrating that the uptake was largely dependent on
the integrity of the Cr transporter.
Cr synthesis in rat cerebellar granule cells
Intracellular precursor accumulation, as well as GAA and
Cr synthesis were investigated by comparing granule cells
incubated with and without [
13 C2,
15 N]Gly and
15 N2-
Arg, (10 mM). Results are summarized in Table 2. After
24 hours of incubation: a) the concentration of
15 N2-Arg
was 56.3 ± 20.4 nmol/mg protein and was similar to that
of the endogenous, unlabelled Arg (55.3 ± 6.5 nmol/mg
protein); b) [
13 C2,
15 N]Gly concentration was 710.5 ±
216.1 nmol/mg protein and was higher than unlabelled
Gly (137.9 ± 29.8 nmol/mg protein); c) [
13C2
15N3]GAA
concentration was 7.4 ± 3.2 nmol/mg protein, which was
34 times the concentration of unlabelled GAA (0.22 ±
0.05 nmol/mg protein). [
13C2
15N3]GAA signal was
62 times the corresponding signal due to the background
noise in control cells; d) [
13C2
15N3]Cr concentration was
1.6 ± 0.4 nmol/mg protein, 2.6% of the concentration of
unlabelled endogenous Cr (62.2 ± 15.3 nmol/mg protein).
[
13C2
15N3]Cr signal was 40 times the corresponding sig-
nal due to the background noise in control samples.
Cr synthesis in rat astrocytes
Astrocytes were incubated for 24 hours with 3 different
concentrations of [
15 N2]Arg and [
13 C2,
15N]Gly (5, 10
and 15 mmol/L). Results are summarized in Table 3.
The intracellular levels of the labelled amino acids
paralleled those in the medium and, except for the con-
centration of 5 mmol/L, were higher than the concen-
trations of unlabelled Arg and Gly, thus demonstrating
their uptake by astrocytes.
After incubation with labelled precursors, the [
13C2,
15N3]
GAA signal in cell extract was strongly increased, reaching
86 times the corresponding background noise in control
samples. [
13C2,
15N3]GAA concentration increased propor-
tionally with the concentration of labelled precursors in
the medium (R
2 > 0.9229; p < 0.002; Figure 3a). The ratio
between [
13C2,
15N3]GAA and the unlabelled, endogenous,
GAA reached 18 (mean value) for the highest precursor
concentration.
We found also a relevant increase of [
13C2
15N3]Cr,
whose signal was significantly higher (up to 121 times
higher) than the corresponding signal in control samples.
No correlation was found between the [
13C2
15N3]Cr
levels and those of labelled precursors in the medium
(Figure 3b) nor with intracellular [
13C2
15N3]GAA. The
concentration of [
13C2
15N3]Cr did not exceed 21% (mean
value) of that of unlabelled endogenous Cr.
Gene expression
To get information about the level of gene expression in
rat astrocytes and cerebellar granule cells we used a PCR-
Real Time relative quantification. To this aim, we com-
pared AGAT, GAMT and SLC6A8 gene expression in dif-
ferent tissues such as blood, kidney and liver. Figure 3
shows that AGAT and SLC6A8 transcripts were highly
expressed in the kidney and GAMT in the liver, while a
very low SLC6A8 expression was found in blood cells.
Leukocytes expression was used as “calibrator” for the
relative assessment of each gene, i.e. the amount of gene
expression in blood cells was used as unit for the quantifi-
cation of the expression in the other tissues. Among the
tissues analyzed, after excluding the kidney in which it was
very high (Figure 4, right panel), AGAT gene expression
was higher in blood cells than in the liver (about 4/1).
Carducci et al. BMC Neuroscience 2012, 13:41
http://www.biomedcentral.com/1471-2202/13/41
Page 5 of 12AGAT was about 1/3 lower in astrocytes than in cerebellar
granule cells (p < 0.005) which, in turn, expressed 37% of
blood cells.
GAMT gene was equally expressed in cerebellar gran-
ule cells and astrocytes (31 and 33% of blood cell
expression, respectively). We found that GAMT expres-
sion in the kidney was 3.5 times higher than in blood
cells. SLC6A8 was about 3 times more expressed in cer-
ebellar granule cells than in astrocytes (p < 0.005). In
order to test the possible influence of experimental con-
ditions on gene expression, SLC6A8 transcripts were
evaluated in P1, P2 and P3 generations of astrocytes by
real time PCR. A stable and overlapping expression was
found along the three cell generations (relative quantifi-
cation expressed as log10 values were 2.06 ± 1.61, 2.09 ±
1.66 and 2.09 ± 1.68 respectively for P1, P2 and P3
generations).
Discussion
Cellular incorporation of stable isotope from nutrient
into downstream metabolites is largely used for the
assessment of metabolic fluxes and the step of quantify-
ing labelled and unlabelled molecules can be achieved
by mass spectrometry, with the advantages of excellent
sensitivity and linear dynamic range, and simultaneous
detection of precursors, products, and associated isoto-
pomers [22]. Labelled Arg and Gly have been success-
fully used to assess AGAT activity in lymphocytes and
lymphoblasts [23] by gas-chromatography-mass spectro-
metry. Using this approach we have developed a new
ESI-MS/MS method and investigated Cr uptake and
synthesis in rat cerebellar granule cells and astrocytes by
incubating the cells with either labelled Cr or with
labelled Arg and Gly, which are the precursors of GAA
and Cr.
Figure 2 Functional expression of CT1 in rat cerebellar granule cells and astrocytes. Incubation of rat cerebellar granule cells (A) and
astrocytes (B) with 1 mmol/L D3Cr in culture medium in presence and absence of 1 mmol/L GPA: intracellular D3Cr mean values are given
along with standard deviation for three different experiments (each sample was analysed two times). The addition in culture medium of GPA
resulted in a marked inhibition of D3Cr uptake (77% and 68% respectively in cerebellar granule cells and astrocytes). D3Cr uptake in absence of
GPA was significantly higher than that in presence of GPA, showing the occurrence of Cr active transport, in cerebellar granule cells as well as in
astrocytes (paired Student’s t-test, N = 6, p < 0.05). Difference in D3Cr uptake between the two cell types was not statistically significant
(unpaired Student’s t-test, N = 6, p = 0.17).
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expression studies showed that in the rat both neurons
and astrocytes are capable to express the enzymatic
machinery to both uptake and synthesize Cr.
Cr uptake
Cr uptake in our study was greatly reduced by GPA, an
inhibitor of CT1 [1,24], thus strongly suggesting that it
mostly happens through this transporter. This functional
result was supported by gene expression analysis, show-
ing that both cell types express CT1. We confirmed pre-
vious data showing that adult rat cerebellar granule cells
express the Cr transporter [15,25-27], that contributes in
a relevant way to the whole intracellular pool of this
compound. A low expression of Cr transporter in the rat
brain soon after the birth and a rapid increase during the
first weeks of life was reported by some studies [25],
while others detected an earlier expression of Cr trans-
porter in embryonic CNS [28]. By contrast, Moller and
Hamprecht [29] found only a feeble Cr uptake in neuro-
blastoma cell line and no Cr transport in neuron-rich pri-
mary cultures from embryonic rat. Thus, our finding
adds to the existing store of partially conflicting results.
Concerning Cr uptake by the astrocytes, our results
confirm those of a previous study based on a kinetic
approach [29]. On this topic, too, conflicting results are
reported in the literature. CT1 was detected in
perivascular astrocytes of the retina [30] and cerebellum
[31], but not in other regions of CNS [31], while no CT1
expression was found in astrocytes by in situ hybridiza-
tion [15,27]. Braissant et al. [21] showed that protracted
exposure to very high levels of NH4Cl induced SLC6A8
transcription and translation in astrocytes, where it
became then detectable by in situ hybridization and
immunohistochemistry, thus suggesting that the SLC6A8
gene may be differentially expressed under different
experimental conditions. To the best of our knowledge,
NH4Cl is the only factor that has been proven to induce
expression of the SLC6A8 gene [21]. However, the relia-
bility of our results is supported by the stability of
SLC6A8 transcription in three generations of cultured
astrocytes (P1, P2 and P3), suggesting that SLC6A8
expression is not affected by the in vitro condition.
As a word of caution, while our findings show that
astrocytes have the capability to express the Cr trans-
porter, and to uptake Cr, we can not rule out that this
capability may be differently expressed in different
conditions.
Cr synthesis
Our findings show that both granule cells and astrocytes
a r ec a p a b l et ou p t a k eA r ga n dG l ya n dt ou s et h e mt o
synthesize GAA and Cr. Again, these functional findings
are supported by gene expression analysis, showing that
Table 2 GAA and Cr synthesis experiments in rat cerebellar granule cells
Concentration of [
15N2]Arg and [
13C2,
15N]Gly in the medium
(mmo1/L)
[
15N2]Arg in the cells
(nmol/mg protein)
Arg in the cells
(nmol/mg
protein)
[
15N2]Arg/Arg
0 1.6 ± 0.8 153.4 ± 105.3 0.009 ± 0.001
10 56.3 ± 20.4
NS 55.3 ± 6.5 1.00 ± 0.25
[
13C2,
15N]Gly in the cells
(nmol/mg protein)
Gly in the cells
(nmol/mg
protein)
13C2,
15N]Gly/Gly
0 1.8 ± 1.2 470.8 ± 232.7 0.007 ± 0.004
10 710.5 ± 216.1 ** 137.9 ± 29.8 5.08 ± 0.68
[
13C2
15N3]GAA in the cells(nmol/mg
protein)
GAA in the cells
(nmol/mg
protein)
[
13C2
15N3]GAA/
GAA
0 0.12 ± 0.07 2.08 ± 1.43 0.085 ± 0.029
10 7.4 ± 3.2 * 0.22 ± 0.05 33.3 ± 7.9
[
13C2
15N3]Cr in the cells
(nmol/mg protein)
Cr in the cells
(nmol/mg
protein)
[
13C2
15N3]Cr/Cr
0 0.04 ± 0.02 261.3 ± 138.4 < 0.001
10 1.6 ± 0.4** 62.2 ± 15.3 0.027 ± 0.007
Intracellular concentrations of Gly, [
13C2,
15N]Gly, Arg, [
15N2]Arg, GAA, [1,2-
13C2,
15N3]GAA, Cr, and [1,2-
13C2,
15N3]Cr after 24 hours in vitro incubation with 10 mmol/
L[
15N2]Arg and 10 mmol/L [
13C2,
15N]Gly. Zero concentration in the first column (first line) corresponds to cells incubated in medium without labeled precursors.
The value reported of labeled compounds is due to background noise. The statistical significance of the differences between intracellular concentrations of
labeled and unlabeled compounds was assessed by paired Student’s t-test: NS not significant, * p < 0.05, ** p < 0.01. The intracellular concentration of [
13C2,
15N]
Gly was significantly higher than that of Gly and the concentration of [
15N2]Arg was similar to that of Arg. Accordingly, the intracellular [
13C2
15N3]GAA
concentration was significantly higher than GAA concentration whereas [
13C2
15N3]Cr is significantly lower than Cr. The ratios express the relative intracellular
availability of labeled and unlabeled forms (right column).
Carducci et al. BMC Neuroscience 2012, 13:41
http://www.biomedcentral.com/1471-2202/13/41
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that are required to synthesize Cr from Arg and Gly,
which have their own transporters at the blood brain bar-
rier and on the plasma membrane of nervous cells
[32-35]. We found that labelled Gly was taken up by both
astrocytes and neurons in a quantity larger than labelled
Arg (Table 2 and 3). That probably depends on different
characteristics of the corresponding transporters, whose
investigation however was outside the scope of our
paper. Previous studies demonstrated GAMT activity in
neuroblastoma cell lines [16]. They also demonstrated Cr
synthesis from Gly in astroglial cells (at a rate dependent
on Arg and Methionine levels in the substrate [17]), and
in brain cell 3D cultures (that are able to convert the
G A At a k e n - u pf r o mm e d i u mi n t oC r[ 3 6 ] ) .M o r e o v e r ,
AGAT and (to a lesser extent) GAMT mRNA were ubi-
quitously found in the adult rat brain by in situ hybridi-
zation [15].
Cr synthesis vs. Uptake
An important difference arises in our data between Cr
synthesis and uptake when we consider the magnitude
o ft h er e s u l t s .C ru p t a k ew a si no u rh a n d sav e r ye f f i -
cient process in both granule cells and astrocytes. After
incubation with labelled Cr the 91% and 99% of the
total intracellular Cr content, respectively in neurons
and in astrocytes, is due to transport. This effect is very
robust and sizable. By contrast, after 24 hours cell incu-
bation with high concentrations of Cr precursors Arg
and Gly, the de novo synthesized Cr was only about
2.7% (in the case of neurons) and 12-21% (in the case of
astrocytes). The remaining unlabelled Cr could be
ascribed to pre-existing intracellular Cr pool, to calf
serum in culture medium (see methods) and to de novo
synthesis starting from unlabelled precursors. However
the contribution of unlabelled precursors to Cr synthesis
is relatively negligible since their intracellular concentra-
tions were minor or equal to labelled ones. Furthermore,
it should be noted that the intermediate labelled product
GAA was highly available for Cr synthesis in both cell
types, increasing 33 times in neurons and up to about
18 times in astrocytes (Tables 2 and 3). In astrocytes it
was possible to study the relationship between precur-
sors concentration and GAA or Cr content. A linear
Table 3 GAA and Cr synthesis experiments in rat astrocytes
Concentration of [
15N2]Arg and [
13C2,
15N]Gly
in the medium (mmol/L)
[
15N2]Arg in the cells
(nmol/mg protein)
Arg in the cells
(nmol/mg protein)
[
15N2]Arg/Arg
0 1.8 ± 1.1 172.0 ± 78.2 0.01 ± 0.00
5 137.9 ± 71.6
NS 145.5 ± 73.4 1.12 ± 0.52
10 504.0 ± 390.0 * 178.6 ± 137.9 3.43 ± 1.66
15 957.4 ± 500.45 ** 215.5 ± 132.5 6.74 ± 4.72
[
13C2,
15N]Gly in the cells
(nmol/mg protein)
Gly in the cells
(nmol/mg protein)
[
13C2,
15N]Gly/Gly
0 2.8 ± 0.9 365.7 ± 43.2 0.01 ± 0.00
5 1003.8 ± 1083.3
NS 696.3 ± 604.2 1.28 ± 0.49
10 2205.5 ± 2382.0 * 893.8 ± 958.4 2.53 ± 0.22
15 3213.9 ± 2482.9 * 744.8 ± 512.7 4.43 ± 0.85
[
13C2
15N3]GAA in the cells
(nmol/mg protein)
GAA in the cells
(nmol/mg protein)
[
13C2
15N3]GAA/GAA
0 0.25 ± 0.09 1.46 ± 1.46 0.29 ± 0.14
5 10.34 ± 7.90 * 2.37 ± 2.23 4.47 ± 3.97
10 17.18 ± 13.36 * 1.88 ± 1.87 13.30 ± 14.32
15 21.59 ± 15.00 ** 1.64 ± 1.11 18.18 ± 17.96
[
13C2
15N3]Cr in the cells
(nmol/mg protein)
Cr in the cells
(nmol/mg protein)
[
13C2
15N3]Cr/Cr
0 0.10 ± 0.05 100.4 ± 118.7 0.00 ± 0.00
5 12.13 ± 12.64 * 86.53 ± 71.65 0.12 ± 0.04
10 10.88 ± 8.48 ** 59.48 ± 23.72 0.17 ± 0.08
15 11.00 ± 6.85 ** 48.54 ± 10.58 0.21 ± 0.09
Intracellular concentrations of Gly, [
13C2,
15N]Gly, Arg, [
15N2]Arg, GAA, [1,2-
13C2,
15N3]GAA, Cr and [1,2-
13C2,
15N3]Cr after 24 h in vitro incubation with [
15N2]Arg and
[
13C2,
15N]Gly under different concentrations of labeled precursors in the medium: no labeled precursors (0), 5, 10 and 15 mmol/L. The statistical significance of
the differences between intracellular concentrations of labeled and unlabeled compounds was assessed by paired Student’s t-test: NS not significant, * p < 0.05,
** p < 0.01. The concentrations of [
13C2,
15N]Gly and [
15N2]Arg were significantly higher than those of Gly and Arg (except for cells incubated with [
15N2]Arg
mmol/L), showing that the labeled precursors are highly available into the cells for Cr synthesis. [
13C2,
15N3]GAA concentrations were also significantly higher than
those of GAA, whereas [
13C2,
15N3]Cr levels remained significantly lower than those of Cr. The ratios express the relative intracellular availability of labeled and
unlabeled forms (right column).
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Page 8 of 12relationship was found for GAA, while no such relation-
ship was found for Cr. Taken together, these results
suggest that in brain cells both Cr synthesis and uptake
are possible, and that under the in vitro conditions we
used the latter is more efficient than the former. More-
over, they suggest that the most critical step in the
synthesis of Cr by brain cells is the conversion of GAA
into Cr, both in neurons and in astrocytes. We do not
exactly know why the conversion of GAA into Cr is so
limited. Tachikawa et al. [18] demonstrated by an
immunohistochemical approach a preferential glial
expression of GAMT coupled with a preferential neuro-
nal expression of ubiquitous mitochondrial CK in the
adult mouse brain. This pattern of enzyme segregation
suggested that neuronal Cr is supplied to nervous cells
by local glial cells [18], a hypothesis later supported by
some of us [37]. In this complex homeostatic model,
which mimics the general separation between sites of Cr
synthesis and utilization outside the CNS [1], the possi-
ble pivotal role of GAA remains to be clarified. Apart
from endogenous synthesis, GAA is up taken by nervous
cells via Cr [18] and Taurine [38] transporters and in
brain parenchyma it is converted to Cr even if in a low
proportion (29%) [36].
T h i si s s u ew a sf u r t h e ra d d r e s s e db ye x p l o r i n gt h ec o -
expression of AGAT, GAMT and SLC6A8 proteins in rat
Figure 3 Functional expression of GAMT and AGAT in rat astrocytes. Intracellular [
13 C2,
15N3]GAA (A) and [
13C2,
15N3]Cr (B) concentrations in
function of [
13C2,
15N]Gly and[
15 N2]Arg concentrations in culture medium, in three sets of cell samples (experiment 1, 2 and 3) are reported. To
test the correlation among the intracellular concentration of labelled products and the precursor concentrations in culture medium, linear
regression analysis was performed. Whereas there was a linear correlation for labelled GAA (p < 0.0022), no clear and consistent linear correlation
for labelled Cr was found. Both graphs show that the cultures of experiment 3 yielded a lesser amount of GAA and Cr. Inspection of the cultures
did not provide any obvious explanation for this result.
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Page 9 of 12grey matter cells [27,36]. These studies suggested that
GAA and Cr synthesis may occur in different cells, and
that GAA needs to be transferred between cells to be
converted into Cr. By providing functional evidence that
the conversion of GAA into Cr by brain cells is a quanti-
tatively limited process, our findings do provide some
support to that hypothesis. Alternatively, we should not
underestimate the possible limiting effect of the availabil-
ity of other metabolites involved in Cr homeostasis, such
as S-adenosylmetionine [29], even if the limiting effect of
this metabolite on Cr synthesis is considered not relevant
under normal condition [1].
Clinical implications
The presence of CT1 in both astrocytes and cerebellar
granule cells, as well as in the endothelium of brain
capillaries [39], and in choroid plexus during the embryo-
nic development [28] strongly supports the view that
blood Cr supply is an important source of brain Cr in
physiological conditions. This conclusion is compatible
with the metabolic pattern detected in patients affected
by CT1 deficiency [9,40] as well as with the restoration of
brain Cr under Cr supplementation observed in the
defects of Cr synthesis: in AGAT deficiency (differently
from GAMT deficiency, where GAA accumulates and
competes with Cr for the CT1 transporter) 40% and 80%
restoration of normal brain Cr level was obtained after 3
and 9 months of treatment, respectively [9,11]. A dosage
as low as 100 mg/kg/bw/day was sufficient to replenish
60% of brain Cr and prevents the emergence of the dis-
ease in an early diagnosed and treated child with AGAT
deficiency [9]. This support the view that Cr transport is
Figure 4 Relative quantification of gene expression using Real Time PCR. Blood expression level is used as calibrator (Relative quantification
(RQ) = 1). Panels at right side (A1, B1, C1) are a magnification of those on the left side (A, B, C) excluding tissues with higher expression level.
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Page 10 of 12probably much more efficient during fetal to perinatal
and postnatal stages [28]. The increase of brain Cr
observed in normal subjects under protracted Cr loading
is much less relevant (3.5-13.3%), notwithstanding the
concomitant increase of blood Cr from 50 to 800 μmol/L
[41]. Similar results, which have been confirmed in ani-
mal models [42-44], overall support the view that Cr pool
in CNS is subjected to a homeostatic control.
The above results may offer an explanation of the
conflicting results that were obtained in patients affected
by CT1 deficiency when treated with the Cr precursors
in order to stimulate the endogenous synthesis of Cr.
Our data suggest that Cr synthesis by brain cells may be
limited, in such a way to possibly provide only a limited
amount of the Cr that is needed by the brain.
Some limitations inherent to our study suggest cau-
tion in extrapolating our results to the in vivo condi-
tions. In fact, we investigated only two kinds of cells
from the cerebellum, while different brain regions and
cells could be differently equipped in term of CK activity
and related Cr availability [31]. Moreover, the need of
large supplementation of Cr in patients with deficient
Cr synthesis, and normal or increased CSF Cr - but not
brain
1 H-MRS Cr - in few CT1 deficient patients before
[45] or during Cr treatment [5,13], remain to be
explained. The recently developed Cr transporter knock-
out mice, that mimics several aspects of the human dis-
ease, will provide an exciting opportunity to verify
different models of Cr transport and synthesis inside the
CNS [46].
Summing up, while further research is needed to fully
understand to what extent these in vitro results are rele-
vant to the in vivo situation, our results show that both
astrocytes and neurons possess the capability to both
synthesize and uptake Cr, but that the latter is probably
more robust than the former.
Abbreviations
Arg: arginine; AGAT L-arginine:glycine amidinotransferase; Cr: creatine; [
13
C2,
15 N]Gly: [
13 C2,
15 N]glycine; CT1: creatine transporter; D3Cr: D3-creatine;
GAA: guanidinoacetic acid; GAMT: S-adenosylmethionine:guanidinoacetate
N-methyltransferase; Gly: glycine; GPA: β-guanidinopropionate; [
15 N2]Arg: L-
[guanido-
15 N2]arginine; SLC6A8: creatine transporter gene; CNS: central
nervous system; ESI-MS/MS: electrospray ionization tandem mass
spectrometry; [1,2-
13 C2]GAA:
13C2-guanidinoacetic acid; [
13 C2,
15N3]GAA: [1,2-
13 C2,
15N3]guanidinoacetic acid; [
13 C2,
15N3]Cr: [1,2-
13 C2,
15N3]creatine.
Author details
1Department of Experimental Medicine, La Sapienza Università di Roma, Viale
del Policlinico 155, Rome 00161, Italy.
2Department of Neuroscience,
Ophthalmology and Genetics, University of Genova, Via De Toni, 5, Genoa
16132, Italy.
3Department of Oncology, Biology and Genetics, University of
Genova, Largo Rosanna Benzi, 10, Genoa 16132, Italy.
4Department of
Physics, University of Genova, Via Dodecaneso, 33, Genoa 16146, Italy.
5Dept
of Child Neurology and Psychiatry, La Sapienza Università di Roma, Via dei
Sabelli 108, Rome 00185, Italy.
6Department of Molecular Medicine, La
Sapienza Università di Roma, Viale Regina Elena 324, Rome 00161, Italy.
Authors’ contributions
All Authors have each made a substantial contribution so as to qualify for
authorship.
Specifically: a) CC, SS, and IA set up the new MS/MS methods for the
intracellular assessment of labelled and unlabelled metabolites. They also
were involved in the development of the experimental design and
cooperated in the interpretation of the metabolic results; b) CC and CA
performed genetic and metabolic molecular studies, interpreted genetic
results and cooperated in the discussion concerning the linkage between
biochemical and molecular results; c) EA, ST, EG, MR, and TF developed the
in vitro model; arranged and accomplished cell coltures with labelled Cr and
Cr precursors; d) VL and MB conceived and developed the experimental
design, addressed the discussion on the interpretation of the results and
coordinated the collaborative study. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 August 2011 Accepted: 26 April 2012
Published: 26 April 2012
References
1. Wyss M, Kaddurah-Daouk R: Creatine and creatinine metabolism. Physiol
Rev 2000, 80:1107-1212.
2. Balestrino M, Lensman M, Parodi M, Perasso L, Rebaudo R, Melani R,
Polenov S, Cupello A: Role of creatine and phosphocreatine in neuronal
protection from anoxic and ischemic damage. Amino Acids 2002,
23:221-229.
3. Item CB, Stöckler-Ipsiroglu S, Stromberger C, Mühl A, Alessandrì MG,
Bianchi MC, Fornai F, Cioni G: Arginine:glycine amidinotransferase
deficiency: the third inborn error of creatine metabolism in humans. Am
J Hum Genet 2001, 69:1127-1133.
4. Stöckler S, Holzbach U, Hanefeld F, Marquartdt I, Helms G, Requart M,
Hänicke W, Frahm J: Creatine deficiency in the brain: a new, treatable
inborn error of metabolism. Pediatr Res 1994, 36:409-413.
5. Cecil KM, Salomons GS, Ball WS, Wong B, Chuck G, Verhoeven NM,
Jakobs C, DeGraw TJ: Irreversible brain creatine deficiency with elevated
serum and urine creatine: a creatine transporter defect? Ann Neurol 2001,
49:401-404.
6. Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS,
Degrauw TJ, Jakobs C: X-linked creatine-transporter gene (SLC6A8)
defect: A new creatine-deficiency syndrome. Am J Hum Genet 2001,
68:1497-1500.
7. Bianchi MC, Tosetti M, Fornai F, Alessandri MG, Cipriani P, De Vito G,
Canapicchi R: Reversible brain creatine deficiency in two sisters with
normal blood creatine level. Ann Neurol 2000, 47:511-513.
8. Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, Appleton R,
Araújo HC, Duran M, Ensenauer R, Fernandez-Alvarez E, Garcia P, Grolik C,
Item CB, Leuzzi V, Marquardt I, Mühl A, Saelke-Kellermann RA, Salomons GS,
Schulze A, Surtees R, van der Knaap MS, Vasconcelos R, Verhoeven NM,
Vilarinho L, Wilichowski E, Jakobs C: GAMT deficiency: features, treatment,
and outcome in an inborn error of creatine synthesis. Neurology 2006,
67:480-494.
9. Battini R, Alessandrì MG, Leuzzi V, Moro F, Tosetti M, Bianchi MC, Cioni G:
Arginine:glycine amidinotransferase (AGAT) deficiency in a newborn:
early treatment can prevent phenotypic expression of the disease. J
Pediatr 2006, 148:828-830.
10. Schulze A, Hoffmann GF, Bachert P, Kirsch S, Salomons GS, Verhoeven NM,
Mayatepek E: Presymptomatic treatment of neonatal guanidinoacetate
methyltransferase deficiency. Neurology 2006, 67:719-721.
11. Bianchi MC, Tosetti M, Battini R, Leuzzi V, Alessandri MG, Carducci C,
Antonozzi I, Cioni G: Treatment monitoring of brain creatine deficiency
syndromes: a 1H- and 31P-MR spectroscopy study. Am J Neuroradiol
2007, 28:548-554.
12. Leuzzi V, Alessandrì MG, Casarano M, Battini R, Cioni G: Arginine and
glycine stimulate creatine synthesis in creatine transporter 1-deficient
lymphoblasts. Anal Biochem 2008, 375:153-155.
13. Chilosi A, Leuzzi V, Battini R, Tosetti M, Ferretti G, Comparini A, Casarano M,
Moretti E, Alessandri MG, Bianchi MC, Cioni G: Treatment with L-arginine
Carducci et al. BMC Neuroscience 2012, 13:41
http://www.biomedcentral.com/1471-2202/13/41
Page 11 of 12improves neuropsychological disorders in a child with creatine
transporter defect. Neurocase 2008, 14:151-161.
14. Fons C, Sempere A, Arias A, López-Sala A, Póo P, Pineda M, Mas A,
Vilaseca MA, Salomons GS, Ribes A, Artuch R, Campistol J: Arginine
supplementation in four patients with X-linked creatine transporter
defect. J Inherit Metab Dis 2008, 31:724-728.
15. Braissant O, Henry H, Loup M, Eilers B, Bachmann C: Endogenous synthesis
and transport of creatine in the rat brain: an in situ hybridization study.
Brain Res Mol Brain Res 2001, 86:193-201.
16. Daly MM: Guanidinoacetate methyltransferase activity in tissues and
cultured cells. Arch Biochem Biophys 1985, 236:576-584.
17. Dringen R, Verleysdonk S, Hamprecht B, Willker W, Leibfritz D, Brand A:
Metabolism of glycine in primary astroglial cells: synthesis of creatine,
serine, and glutathione. J Neurochem 1998, 70:835-840.
18. Tachikawa M, Fujinawa J, Takahashi M, Kasai Y, Fukaya M, Sakai K,
Yamazaki M, Tomi M, Watanabe M, Sakimura K, Terasaki T, Hosoya K:
Expression and possible role of creatine transporter in the brain at the
blood-cerebrospinal fluid barrier as transporting protein of
guanidinoacetate, an endogenous convulsant. J Neurochem 2008,
107:768-778.
19. Robello M, Amico C, Cupello A: Regulation of GABA-A receptor in
cerebellar granule cells inculture: Differential involvement of kinase
activities. Neuroscience 1993, 53:131-138.
20. Thellung S, Villa V, Corsaro A, Pellistri F, Venezia V, Russo C, Aceto A,
Robello M, Florio T: ERK1/2 and p38 MAP kinases control prion protein
fragment 90-231-induced astrocyte proliferation and microglia
activation. GLIA 2007, 55:1469-1485.
21. Braissant O, Cagnon L, Monnet-Tschudi F, Speer O, Wallimann T,
Honegger P, Henry H: Ammonium alters creatine transport and synthesis
in a 3D culture of developing brain cells, resulting in secondary cerebral
creatine deficiency. Eur J Neurosci 2008, 27:1673-1685.
22. Yuan J, Bennett BD, Rabinowitz JD: Kinetic flux profiling for quantitation
of cellular metabolic fluxes. Nat Protoc 2008, 3:1328-1340.
23. Verhoeven NM, Schor DS, Roos B, Battini R, Stöckler-Ipsiroglu S,
Salomons GS, Jakobs C: Diagnostic enzyme assay that uses stable
isotope-labelled substrates to detect L-arginine:glycine
amidinotransferase deficiency. Clin Chem 2003, 49:803-805.
24. Balestrino M, Gandolfo C, Perasso L: Controlling the flow of energy:
inhibition and stimulation of the creatine transporter. Curr Enzym Inhib
2009, 5:223-233.
25. Saltarelli MD, Bauman AL, Moore KR, Bradley CC, Blakely RD: Expression of
the rat brain creatine transporter in situ and in transfected HeLa cells.
Dev Neurosci 1996, 18:524-534.
26. Hiel H, Happe HK, Warr WB, Morley BJ: Regional distribution of a creatine
transporter in rat auditory brainstem: an in-situ hybridization study. Hear
Res 1996, 98:29-37.
27. Braissant O, Henry H: AGAT, GAMT and SLC6A8 distribution in the central
nervous system, in relation to creatine deficiency syndromes: A review. J
Inherit Metab Dis 2008, 31:230-239.
28. Braissant O, Henry H, Villard AM, Speer O, Wallimann T, Bachmann C:
Creatine synthesis and transport during rat embryogenesis:
spatiotemporal expression of AGAT, GAMT and CT1. BMC Dev Biol 2005,
26:5-9.
29. Möller A, Hamprecht B: Creatine transport in cultured cells of rat and
mouse brain. J Neurochem 1989, 52:544-550.
30. Acosta ML, Kalloniatis M, Christie DL: Creatine transporter localization in
developing and adult retina: importance of creatine to retinal function.
Am J Physiol Cell Physiol 2005, 289:1015-1023.
31. Mak CS, Waldvogel HJ, Dodd JR, Gilbert RT, Lowe MT, Birch NP, Faull RL,
Mak Christie DL: Immunohistochemical localisation of the creatine
transporter in the rat brain. Neuroscience 2009, 163:571-585.
32. Stoll J, Wadhwani KC, Smith QR: Identification of the cationic amino acid
transporter (systemy+) of the rat blood-brain barrier. J Neurochem 1993,
60:1956-1959.
33. Braissant O, Gotoh T, Loup M, Mori M, Bachmann C: L-arginine uptake, the
citrulline-NO cycle and arginase II in the rat brain: an in situ
hybridization study. Brain Res Mol Brain Res 1999, 70:231-241.
34. O’Kane RL, Viña JR, Simpson I, Zaragozá R, Mokashi A, Hawkins RA: Cationic
amino acid transport across the blood-brain barrier is mediated
exclusively by system y+. Am J Physiol Endocrinol Metab 2006, 291:
E412-E419.
35. Hosoya K, Ichikawa T, Akanuma S, Hirose S, Tachikawa M: Glycine and L-
arginine transport in cultured Müller glial cells (TR-MUL). Neurochem Int
2010, 57:262-268.
36. Braissant O, Béard E, Torrent C, Henry H: Dissociation of AGAT, GAMT and
SLC6A8 in CNS: Relevance to creatine deficiency syndromes. Neurobiol
Dis 2010, 37:423-433.
37. Lunardi G, Parodi A, Perasso L, Pohvozcheva AV, Scarrone S, Adriano E,
Florio T, Gandolfo C, Cupello A, Burov SV, Balestrino M: The creatine
transporter mediates the uptake of creatine bybrain tissue, but not the
uptake of two creatine-derived compounds. Neuroscience 2006,
142:991-997.
38. Tachikawa M, Kasai Y, Yokoyama R, Fujinawa J, Ganapathy V, Terasaki T,
Hosoya K: The blood-brain barrier transport and cerebral distribution of
guanidinoacetate in rats: involvement of creatine and taurine
transporters. J Neurochem 2009, 111:499-509.
39. Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K,
Ohtsuki Terasaki T: The blood-brain barrier creatine transporter is a major
pathway for supplying creatine to the brain. J Cereb Blood Flow Metab
2002, 22:1327-1335.
40. de Grauw TJ, Salomons GS, Cecil KM, Chuck G, Newmeyer A, Schapiro MB,
Jakobs C: Congenital creatine transporter deficiency. Neuropediatrics 2002,
33:232-238.
41. Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J: Increase of total
creatine in human brain after oral supplementation of creatine-
monohydrate. Am J Physiol 1999, 277:R698-R704.
42. Ipsiroglu OS, Stromberger C, Ilas J, Hoger H, Muhl A, Stockler-Ipsiroglu S:
Changes of tissue creatine concentrations upon oral supplementation of
creatine-monohydrate in various animal species. Life Sci 2001,
69:1805-1815.
43. Perasso L, Cupello A, Lunardi GL, Principato C, Gandolfo C, Balestrino M:
Kinetics of creatine in blood and brain after intraperitoneal injection in
the rat. Brain Research 2003, 974:37-42.
44. Kan HE, Meeuwissen E, Veltien A, Isbrandt D, Heerschap A: Creatine uptake
kinetics in brain and skeletal muscle of GAMT deficient knockout mice.
Proc Intl Soc Mag Reson Med 2006, 14:1484.
45. Almeida LS, Verhoeven NM, Roos B, Valongo C, Cardoso ML, Vilarinho L,
Salomons GS, Jakobs C: Creatine and guanidinoacetate: diagnostic
markers for inborn errors in creatine biosynthesis and transport. Mol
Genet Metab 2004, 82:214-219.
46. Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT,
Vorhees CV: Creatine Transporter (CrT; Slc6a8) knocout mice as a model
of human CrT deficiency. PloS One Jan 2011, 13:e16187.
doi:10.1186/1471-2202-13-41
Cite this article as: Carducci et al.: In vitro study of uptake and synthesis
of creatine and its precursors by cerebellar granule cells and astrocytes
suggests some hypotheses on the physiopathology of the inherited
disorders of creatine metabolism. BMC Neuroscience 2012 13:41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Carducci et al. BMC Neuroscience 2012, 13:41
http://www.biomedcentral.com/1471-2202/13/41
Page 12 of 12